Pyridyl-Cyclopentadiene Re(CO)(2) Complexes as a Compact Core Systems for SPECT Ligand Development

Nickel(II) and Palladium(II) Complexes with η5:κ1(N)-Coordinated Dicarbollide Ligands Containing Pendant Pyridine Group

A series of C- and B-substituted nido-carborane derivatives with a pendant pyridyl group was prepared. The synthesized compounds were used as ligands in the complexation reactions with bis(triphenylphosphine)nickel(II) and palladium(II) chlorides to give six new metallacomplexes with unusual η5:κ1(N)-coordination of the metal center. The single crystal structures of 1-(NC5H4-2'-S)-1,2-C2B10H11, 1-(NC5H4-2'-CH2S)-1,2-C2B10H11, Cs [7-(NC5H4-2'-CH2S)-7,8-C2B9H11] closo- and nido-carboranes and 3-Ph3P-3-(4(7)-NC5H4-2'-S)-closo-3,1,2-NiC2B9H10 and 3-Ph3P-3-(4(7)-NC5H4-2'-CH2S)-closo-3,1,2-NiC2B9H10 metallacarboranes were determined using single crystal X-ray diffraction.

Anticancer and Antibiotic Rhenium Tri- and Dicarbonyl Complexes: Current Research and Future Perspectives

Organometallic compounds are increasingly recognized as promising anticancer and antibiotic drug candidates. Among the transition metal ions investigated for these purposes, rhenium occupies a special role. Its tri- and dicarbonyl complexes, in particular, attract continuous attention due to their relative ease of preparation, stability and unique photophysical and luminescent properties that allow the combination of diagnostic and therapeutic purposes, thereby permitting, e.g., molecules to be tracked within cells. In this review, we discuss the anticancer and antibiotic properties of rhenium tri- and dicarbonyl complexes described in the last seven years, mainly in terms of their structural variations and in vitro efficacy. Given the abundant literature available, the focus is initially directed on tricarbonyl complexes of rhenium. Dicarbonyl species of the metal ion, which are slowly gaining momentum, are discussed in the second part in terms of future perspective for the possible developments in the field.

Cyclopentadienyl-Based Anticancer Drugs: Improvement of Cytotoxic Activity through Functionalisation of the π Ligand

Cytotoxic complexes containing molybdenum are widely studied as a potential substitution for commercially used drugs that often suffer from pronounced side effects and cellular resistance. Compounds of the type [(η⁵ -Cp')Mo(CO)₂ (^N,N L)][BF₄ ], where Cp is cyclopentadienyl and ^N,N L is a bidentate ligand, are well known for their strong anticancer activity. It is a generally accepted paradigm that the nature of the coordinated ^N,N L ligand has a major impact on the cytotoxicity. In this study, a series of new functionalised Cp complexes of molybdenum was synthesised from derivatised fulvenes as π-ligand precursors. Indeed, the coordination sphere's modulation by various N,N-chelating ligands afforded species active toward leukemic cell line MOLT-4 with IC₅₀ values depending on the character of the N,N-chelator used. However, following study clearly showed that functionalisation of the Cp ring with an amine moiety considerably improved cytotoxicity. These results are of crucial importance for the future design of highly active cytotoxic drugs, as modification of cyclopentadienyl is believed to have a minor effect on biological activity.

Metal-free C(sp3)–H bond sulfonyloxylation of 2-alkylpyridines and alkylnitrones

Direct transformation of an inert C(sp³)–H bond of 2-alkylpyridines and nitrones into a C–OSO₂R bond has been described.

Reactivity of a trinuclear ruthenium complex involving C–H activation and insertion of alkene

Synthesis, structure and reactivity of a pyridyl-substituted indenyl trinuclear ruthenium complex were researched.